Brian Hill, MD
In an interview, Healio spoke with Brian Hill, MD, PhD, Director of the Lymphoid Malignancies Program and Staff Physician at the Cleveland Clinic Taussig Cancer Institute, about:
- recent advancements in MCL treatment, specifically the introduction of oral BTK inhibitors and CAR T-cell therapies;
- major risk factors for developing MCL, including factors not included in the MIPI score;
- emerging therapies and drugs for MCL treatment, and the potential utility of non-covalent BTK inhibitors;
- areas of unmet need in MCL, and questions on how to deal with patients who are unsuited for CAR T-cell therapies;
- how he approaches putting together a treatment plan for an MCL patient;
- and how to address quality of life in a patient with MCL, a notoriously aggressive and persistent cancer.